BindingDB logo
myBDB logout

23 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
25987375 20 Discovery of a novel Kv7 channel opener as a treatment for epilepsy.EBI Pfizer Inc
25017033 148 Potent and selective inhibitors of the TASK-1 potassium channel through chemical optimization of a bis-amide scaffold.EBI University of Kansas Specialized Chemistry Center
23121096 86 Ion channels as therapeutic targets: a drug discovery perspective.EBI Pfizer Inc
20020710 30 Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.EBI Icagen Inc
22793372 66 Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.EBI Vanderbilt University Medical Center
22770500 219 3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain models.EBI AstraZeneca
22910039 66 Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator.EBI Vanderbilt University Medical Center
24900334 89 N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.EBI TBA
17483457 58 A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.EBI Abbott Laboratories
12930139 22 Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
21296466 20 Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators.EBI Hebei Medical University
20855211 91 Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives.EBI Abbott Laboratories
12852750 2 (S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
31223450 2 Synthesis and Optimization of KEBI University of Pittsburgh
31668424 17 An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.EBI Marquette University
31815462 15 Synthesis and Pharmacological Characterization of Conformationally Restricted Retigabine Analogues as Novel Neuronal Kv7 Channel Activators.EBI University Federico II of Naples
31416667 24 Design and evaluation of pyrazolopyrimidines as KCNQ channel modulators.EBI AbbVie Inc.
24900517 3 Potassium channel modulators as possible treatment for pain: patent highlight.EBI Therachem Research Medilab (India) Pvt. Ltd.
17489574 1 Kv7 (KCNQ) channel modulators and neuropathic pain.EBI NeuroSearch A/S
30327146 29 Novel KEBI GlaxoSmithKline
30061030 13 Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy.EBI Nanjing University of Technology
29706422 5 Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents.EBI Nanjing University of Technology
28626530 71 Discovery of a Series of Indazole TRPA1 Antagonists.EBI Pfizer Inc